Climb Bio Inc. (CLYM)
1.33
0.08 (6.40%)
At close: Mar 13, 2025, 2:00 PM
Company Description
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases.
It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy.
The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024.
Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Climb Bio Inc.
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc |
Contact Details
Address: PMB #117, 2801 Centerville Road Wilmington, Delaware United States | |
| Website | https://eliemtx.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US28658R1068 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | Chief Executive Officer, President & Director |
| Dr. Brett Kaplan M.B.A., M.D. | Chief Operating Officer & Principal Financial Officer |
| Dr. Nishi Rampal M.D. | Senior Vice President of Clinical Development |
| Emily Pimblett CPA | Senior Vice President of Finance & Chief Accounting Officer |
| Janaki Subramanyam M.Sc. | Vice President & Head of Regulatory Affairs |
| Kate Hecht M.B.A. | Senior Vice President of Program Management |